Characteristics of patients with and without abnormalities
| Feature . | Patients without abnormalities in Ph−metaphases (n = 40) . | Patients with abnormalities in Ph−metaphases (n = 8) . | P . |
|---|---|---|---|
| Demographics | |||
| Age at diagnosis, y, median (range) | 51 (25-78) | 50 (37-72) | .9765-150 |
| Sex, male/female | 15/25 | 5/3 | .2515-151 |
| Disease duration, mo, median (range) | 20 (1-85) | 22 (9-69) | .2995-150 |
| Treatment prior to imatinib | |||
| IFN, yes/no | 25/15 | 7/1 | .2405-151 |
| HU, yes/no | 32/8 | 5/3 | .3615-151 |
| Ara-C, yes/no | 9/31 | 5/3 | .0375-151 |
| Ida, yes/no | 5/35 | 4/4 | .0315-151 |
| Other, yes/no | 2/38 | 1/8 | .4295-151 |
| ABMT, yes/no | 4/36 | 2/6 | .2585-151 |
| Phase at starting imatinib | |||
| Newly diagnosed, yes/no | 12/28 | 0/8 | .1745-151 |
| CPI/beyond CP1 | 37/3 | 6/2 | .1895-151 |
| Duration of imatinib therapy, mo, median (range) | 11 (1-23) | 16 (10-24) | .3065-150 |
| Feature . | Patients without abnormalities in Ph−metaphases (n = 40) . | Patients with abnormalities in Ph−metaphases (n = 8) . | P . |
|---|---|---|---|
| Demographics | |||
| Age at diagnosis, y, median (range) | 51 (25-78) | 50 (37-72) | .9765-150 |
| Sex, male/female | 15/25 | 5/3 | .2515-151 |
| Disease duration, mo, median (range) | 20 (1-85) | 22 (9-69) | .2995-150 |
| Treatment prior to imatinib | |||
| IFN, yes/no | 25/15 | 7/1 | .2405-151 |
| HU, yes/no | 32/8 | 5/3 | .3615-151 |
| Ara-C, yes/no | 9/31 | 5/3 | .0375-151 |
| Ida, yes/no | 5/35 | 4/4 | .0315-151 |
| Other, yes/no | 2/38 | 1/8 | .4295-151 |
| ABMT, yes/no | 4/36 | 2/6 | .2585-151 |
| Phase at starting imatinib | |||
| Newly diagnosed, yes/no | 12/28 | 0/8 | .1745-151 |
| CPI/beyond CP1 | 37/3 | 6/2 | .1895-151 |
| Duration of imatinib therapy, mo, median (range) | 11 (1-23) | 16 (10-24) | .3065-150 |